Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to Step 1 registration
Phase I only: Patients must have mean hemoglobin concentration < 10.0 g/dL of 2 measurements (not influenced by RBC transfusion within 7 days of measurement) and having received < 4 units of RBCs within 8 weeks prior to start of treatment OR,
Total hemoglobin >= 9 g/dL (may be post-transfusion)
Pre-transfusion hemoglobin of <= 10 g/dL,
Total hemoglobin >= 9 g/dL (which may be post transfusion)
Hemoglobin < 9 g/dL (hemoglobin may be supported by transfusion, erythropoietin, or other approved hematopoietic growth factors)
Hemoglobin >= 9 g/dL (with or without transfusion support)
hemoglobin ? 9 g/dL; subjects requiring transfusion will be eligible to start study
Hemoglobin ? 9.0 g/dL independent of transfusion and/or growth factors within 3 months prior to randomization
Hemoglobin >= 9 g/dL (with or without transfusion support)
Hemoglobin >= 9 g/dL (with or without transfusion support) within 14 days prior to start of protocol therapy.
Hemoglobin >= 10 g/dl (may achieve by transfusion)
Meet the following laboratory parameters, per the reference range, at least once during the screening period: ANC of at least 1000/?L (Subjects may use growth factor support to achieve ANC eligibility criteria), AST and ALT not higher than 3 x ULN, Calculated creatinine clearance of at least 30 mL/min using a modified Cockcroft-Gault calculation, platelet count of at least 30,000 mm³ (independent of transfusion for 2 weeks), hemoglobin of at least 8.0 g/dL (subjects may receive blood transfusion to achieve hemoglobin eligibility criteria), and total bilirubin not higher than 1.5 x ULN (subjects with Gilbert's Syndrome may have bilirubin higher 1.5 x ULN).
Hemoglobin >= 9 g/dL (transfusion to meet eligibility allowed)
Hemoglobin ? 8 g/dL, with or without transfusion support
Within 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Hemoglobin >= 9.0 g/dL (transfusion allowed).
STRATUM A: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the test
STRATUM B: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the test
STRATUM C: Hemoglobin >= 8.0 g/dL without support of a blood transfusion within 7 days of the test
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)
COHORT 3: ENDOMETRIAL CANCER: Hemoglobin >= 9 mg/dL (transfusion to obtain hemoglobin >= 9 mg/dL within 24 hours prior to dosing is allowed)
Hemoglobin >= 9.0 g/dL independent of transfusion.
Hemoglobin >= 9 g/dL but transfusion allowed
Hemoglobin ? 9 g/dL (uncorrected by RBC transfusion)
REP ELIGIBILITY: Hemoglobin greater than or equal to 8.0 g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is 8 gm/dL)
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Hemoglobin greater than or equal to 8.0 g/dL (Note that this threshold is slightly lower than the initial trial screening parameter since most subjects will require blood transfusion at some point during the protocol treatment, and the established threshold for transfusion is 8 gm/dL)
Hemoglobin ? 9.0 g/dL without transfusion support within 14 days prior to study treatment (erythropoietin or darbepoetin permitted)
Hemoglobin >= 9.0 g/dL (transfusion is allowed to correct anemia).
Hemoglobin >= 8 mg/dL (Note: Transfusion may be used for eligibility outside of 7 days)
Hemoglobin >= 9.0 g/dL\r\n* Patients may have a transfusion of red blood cells to meet the hemoglobin requirement
Hemoglobin >= 9 g/dL (transfusion allowed but must demonstrate stability after transfusion)
Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
Hemoglobin >= 10 g/dL (transfusion to obtain hemoglobin >= 10 g/dL within 24 hours prior to dosing is allowed)
Hemoglobin >= 9 g/dL\r\n* May receive transfusion to meet this goal
Hemoglobin >= 9 g/dL\r\n* Note: Patients requiring transfusion to meet the hemoglobin requirement are not eligible for the study
Hemoglobin of >= 10 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
Hemoglobin >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
Hemoglobin > 10.0 g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)
Hemoglobin >= 7.5 g/dL in the presence of bone marrow involvement independent of transfusion and/or growth factors within 3 months prior to enrollment
Hemoglobin ? 9.0 g/dL (in the absence of transfusion within 2 weeks before randomization)
Hemoglobin >= 9.0 g/dL, which must be stable in the opinion of the investigator without a history of transfusion dependence
Hemoglobin >= 9 g/dL without transfusion dependency
Hemoglobin concentration > 8 g/dL (with or without support)
Hemoglobin >= 9.0 g/dL without transfusion support within the past 28 days (erythropoietin or darbepoetin permitted)
Hemoglobin >= 9 g/dL (with or without support)
Hemoglobin 10 gl/dl (transfusion allowed)
Hemoglobin >= 8 g/dL (may be post-transfusion)
Hemoglobin >= 9 g/dL (SI units 90 g/L) (in the absence of transfusion within 24 hours prior to dosing)
Hemoglobin <9 g/dL (may receive transfusion or erythropoietin to maintain)
Hemoglobin >= 8.0 g/dL without transfusion if stem cells are not available
Hemoglobin (Hb) >= 9 g/dL (independent of transfusion and/or growth factors within 3 months prior to cycle 1 day 1)
Hemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or darbepoetin (Aranesp) for 21 days
Hemoglobin ?9 g/dL, without transfusion support within 7 days preceding the lab assessment.
Hemoglobin >9.0 g/dL (may be maintained by transfusion)
Hemoglobin ?8.0 g/dL with or without transfusion support
Hemoglobin >= 8 g/dL (transfusion allowed)
Hemoglobin >= 9 g/dL (transfusion to meet this criterion is allowed)
Hemoglobin ? 9.0 g/dL without transfusion and/or growth factors in the 3 months prior to randomization
Hemoglobin >= 8.0 g/dL; if patients have a hemoglobin level below 8, blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 8.0 g/dL for 7 days or longer
Hemoglobin > 9 g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 9.0 g/dL for 7 days or longer)
Transfusion dependency defined by transfusion of at least 4 units of RBC (red blood cells) within 8 weeks before Screening; pre-transfusion Hgb (hemoglobin) values must be ? 9 g/dL to be taken into account.
Hemoglobin >= 9 g/dL, without ongoing chronic blood transfusion or colony stimulating factor support to maintain normal levels; principal investigator approval is required; (limited red blood cell [RBC] transfusion is allowed for an acute change in hemoglobin)
Hemoglobin >= 8; transfusion is allowed
Hemoglobin < 8 g/dL within 21 days of initiation of protocol therapy; transfusion may be used to meet hemoglobin eligibility criteria
Must have symptomatic anemia untransfused with hemoglobin < 9.5 g/dL =< 8 weeks prior to randomization or with red blood cells (RBC) transfusion dependence (i.e., >= 2 units/month) confirmed for =< 8 weeks before randomization\r\n* NOTE: For non-transfusion dependent patients (i.e., receiving < 2 units/4 weeks x 8 weeks pre-study) who receive periodic transfusions, the mean 8 week pre-transfusion hemoglobin should be used to determine protocol eligibility and response reference\r\n* For non-transfusion dependent patients, a minimum of 2 pre-transfusion or un-transfused hemoglobin values are required
Hemoglobin >80 g/dL (without transfusion support within 7 days from start of leukapheresis)
Hemoglobin > 9 g/dL (International System [SI] units: 90 g/L) without transfusion support or growth factors within 10 days of starting INC280
Hemoglobin ? 9 g/dL. This criterion must be met without transfusion.
Hemoglobin >= 9 g/dL (after transfusion, if necessary) within 4 weeks of pre-registration
Hemoglobin > 9.0 without transfusion support in the past 28 days
Hemoglobin >= 8 g/dL (may be post-transfusion)
Hemoglobin >=9.0 grams/decilitre(g/dL) (after transfusion if needed)
Hemoglobin >= 9.0 g/dL (90 g/L); previous transfusion is allowed
Hemoglobin =< 10.0 g/dL for males and =< 9.0 g/dL for females (transfusion allowed to achieve or maintain levels)
Hemoglobin ? 8.0 g/dL with or without transfusion support
Hemoglobin >= 10.0 g/dL independent of transfusion
Hemoglobin > 9.0 g/dL (transfusion and/or erythropoiesis stimulating agents [ESA] allowed)
Hemoglobin >= 8 g/dl (transfusion support allowed)
Hemoglobin >= 8.0 g/dl with transfusion support
Has hemoglobin <8.0g/dL. The use of transfusion with pRBC to correct anemia and meet eligibility criteria will not be allowed.
Hemoglobin >= 10 g/dL (after transfusion if necessary)
EXPANSION COHORT ONLY: Hemoglobin >= 9 g/dL; subjects may not have had an RBC transfusion within 7 days of screening assessment
Hemoglobin >= 8 g/dL; if anemia is present to the extent that the hemoglobin is < 8 g/dL, then correction by transfusion is indicated before entry into this study
Hemoglobin ? 9 g/dL (uncorrected by RBC transfusion)
Hemoglobin ? 9 g/dL, (? 8 g/dL for subjects who are transfusion dependent)
Hemoglobin concentration > 8 g/dL (with or without support)
Hemoglobin >= 10 mg/dL (in the absence of transfusion within 24 hours prior to dosing)
Hemoglobin >= 8 g/dL (transfusion support allowed)
Hemoglobin ?9 g/dL, without the need for transfusion in the 2 weeks prior to screening
Hemoglobin ? 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
Hemoglobin >= 10 g/dL (may be post-transfusion)
Hemoglobin at least 10 g/L (transfusion is allowed to achieve hemoglobin of 10 g/L)
Hemoglobin >/= 10.0 g/dL without transfusion support
Hemoglobin >= 9.0 g/dL\r\nNote: patient may receive blood transfusion to achieve a hemoglobin >= 9.1 g/dL; however, hemoglobin must be stable at or above 9 g/dL two weeks prior to dosing
Screening blood counts of the following: Absolute neutrophil count ? 1000/?L, Platelets ? 75,000/?L, Hemoglobin ? 8 g/dL (with transfusion support);
Anemia, defined as hemoglobin <10 gram per deciliter (g/dL) or >2 g/dL below lower limit of normal or both; transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted
Hemoglobin >= 90 g/L independent of transfusion
Hemoglobin >= 8.5 g/dL without transfusion support > 7 days prior to registration
Hemoglobin ?9 g/dL(without transfusion support)
Hemoglobin <10 g/dL (may be determined following transfusion)
Absolute neutrophils count (ANC) ? 1.5 x 10E9/L, platelets ? 100 x 10E9/L, hemoglobin > 9 g/dL (without transfusion or erythropoiesis stimulating agents dependency).